MedTrace Logo

The Effects of ProAlgaZyme on HDL Cholesterol in Individuals With Metabolic Syndrome

NCT00518960 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2007-08-21

No results posted yet for this study

Summary

The purpose of this study is to determine the effectiveness of ProAlgaZyme in increasing levels of HDL 'good' cholesterol and decreasing total cholesterol and C-reactive protein in patients with Metabolic Syndrome.

Conditions

Interventions

DRUG

ProAlgaZyme

Sponsors & Collaborators

  • MAPS Applied Research Center

    collaborator INDUSTRY

  • Health Enhancement Products, Inc.

    lead INDUSTRY

Principal Investigators

  • Terence Pertile, Ph.D. · MAPS Applied Research Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-04-30
Completion
2007-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00518960 on ClinicalTrials.gov